News

BioSpace56m
Regeneron Backs Off 23andMe, Losing Bid to Former CEO
Regeneron did not bid higher on the genetic testing company because of “its assessment of 23andMe’s remaining value,” ...
Pharmaceutical Technology4h
EHA 2025: Regeneron’s Lynozyfic with Amgen’s Kyprolis combo emerges for R/R MM
Lynozyfic’s global sales are projected to reach $707 million by 2031.
Regeneron CEO on 23andMe bid: Trying to balance individual privacy with biotech & genetics research
Regeneron founder, chairman and CEO Dr. Leonard Schleifer joins 'Squawk Box' to discuss the company's bid for 23andMe, ...
Founder of 23andMe buys back company out of bankruptcy auction
TTAM Research Institute, a non-profit public benefit company also founded by Wojcicki, won the auction with a $305 million ...
Why Regeneron Is Falling And Why You Should Avoid It
Regeneron Pharma stock has been in a persistent downtrend for over 280 days. Here's why you should avoid REGN.
Is Regeneron Stock Undervalued At $500?
In light of the significant drop in Regeneron’s stock price, a natural question emerges: is REGN now a viable buying opportunity?
Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day
This was the stock's second consecutive day of gains.
Regeneron to buy bankrupt DNA testing firm 23andMe for $256 million
Drugmaker Regeneron Pharmaceuticals will buy genetic testing firm 23andMe for $256 million through a bankruptcy auction, the ...
Regeneron to buy bankrupt 23andMe, vows ethical use of customer DNA data
Regeneron Pharmaceuticals said on Monday it will buy genomics firm 23andMe Holding for $256 million through a bankruptcy ...
Regeneron, Sanofi Announce Positive Dupixent Results for Atopic Dermatitis
Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is one of the 11 most profitable NASDAQ stocks to buy now. On June 9, Regeneron ...